November 14, 2017 07:14 AM EST
Pharma

Bay­er steps up with $1.55B deal to take a lead role in com­mer­cial­iz­ing Loxo’s can­cer drugs

John Carroll

Editor & Founder

Bay­er is buy­ing in­to the close­ly-watched piv­otal can­cer pro­gram un­der­way at Loxo On­col­o­gy $LOXO. And they are pay­ing big to part­ner on Loxo’s pipeline of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

In blow to com­pounders, FDA reaf­firms tirzepatide short­age is over

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Re­gen­eron forges ahead in fac­tor XI de­spite field’s mixed re­sults

FDA re­jects Zealand Phar­ma's short bow­el syn­drome drug

Mesoblast wins long-await­ed ap­proval for cell ther­a­py

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times